Prograf generics begin to bite at Astellas
This article was originally published in Scrip
Executive Summary
Astellas's total net sales edged up by 2% to ¥772.8 billion ($8.52 billion) in the nine months to December 31st, with growth being constrained by the strong yen and increasing generic competition for top product Prograf (tacrolimus).